人表皮生长因子受体2(HER2)阳性早期乳腺癌(BC)降阶梯策略:西德研究组辅助动态标志物调整的个体化治疗试验最终分析——优化早期BC风险评估与治疗反应预测的HER2及激素受体阳性II期随机试验——12周疗效、安全性和预测标志物
这项前瞻性新辅助II期试验将375例HER2阳性/激素受体(HR)阳性早期乳腺癌患者随机分配至12周T-DM1(联合或不联合内分泌治疗)或曲妥珠单抗联合内分泌治疗,主要终点病理完全缓解(pCR)率分别为41.0%、41.5%和15.1%(P < .001)。早期应答者pCR率35.7%,非应答者19.8%(OR 2.2,95%CI 1.24-4.19)。T-DM1组1-2级毒性更常见,总体毒性低。
要点
- 12周新辅助T-DM1联合或不联合内分泌治疗,pCR率分别为41.0%和41.5%,曲妥珠单抗联合内分泌治疗为15.1%(P < .001)。
- 早期应答者(可评估应答患者的67%)pCR率35.7%,非应答者19.8%(OR 2.2,95%CI 1.24-4.19)。
- T-DM1组1-2级毒性(血小板减少、恶心、肝酶升高)更常见,治疗相关严重不良事件T-DM1组5.3% vs 曲妥珠单抗联合内分泌治疗组3.1%。
核心结论
- 12周新辅助T-DM1联合或不联合内分泌治疗可获得有临床意义的pCR率,使相当数量患者免于全身化疗的不良反应。
研究设计与样本
- 前瞻性新辅助II期随机试验,375例HER2阳性/HR阳性早期乳腺癌患者(筛查463例)随机分配至12周T-DM1联合或不联合内分泌治疗或曲妥珠单抗联合内分泌治疗。
- 主要终点为pCR(ypT0/is/ypN0),早期应答通过3周治疗后空心针穿刺活检评估(Ki-67增殖下降≥30%或细胞学应答),次要终点包括安全性和早期应答对pCR的预测价值。
主要发现
- T-DM1组pCR率41.0%,T-DM1联合内分泌治疗组41.5%,曲妥珠单抗联合内分泌治疗组15.1%(P < .001)。
- 早期应答者(占可评估应答患者的67%)pCR率35.7%,非应答者19.8%(OR 2.2,95%CI 1.24-4.19)。
- T-DM1组1-2级毒性更常见,尤其是血小板减少、恶心和肝酶升高;治疗相关严重不良事件T-DM1组5.3% vs 曲妥珠单抗联合内分泌治疗组3.1%。
关键数值与推荐
- T-DM1组pCR率41.0%,T-DM1联合内分泌治疗组41.5%,曲妥珠单抗联合内分泌治疗组15.1%(P < .001)。
- 早期应答者pCR率35.7% vs 非应答者19.8%(OR 2.2,95%CI 1.24-4.19)。
- 治疗相关严重不良事件T-DM1组5.3% vs 曲妥珠单抗联合内分泌治疗组3.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Human epidermal growth factor receptor 2 (HER2)-positive/hormone receptor (HR)-positive breast cancer is a distinct subgroup associated with lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little is known about the efficacy of the combination of endocrine therapy (ET) with trastuzumab or with the potent antibody-cytotoxic, anti-HER2 compound trastuzumab emtansine (T-DM1) with or without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer) compares pathologic complete response (pCR) rates of T-DM1 versus trastuzumab with ET in early HER2-positive/HR-positive breast cancer. Patients and Methods In this prospective, neoadjuvant, phase II trial, 375 patients with early breast cancer with HER2-positive and HR-positive status (n = 463 screened) were randomly assigned to 12 weeks of T-DM1 with or without ET or to trastuzumab with ET. The primary end point was pCR (ypT0/is/ypN0). Early response was assessed in 3-week post-therapeutic core biopsies (proliferation decrease ≥ 30% Ki-67 or cellularity response). Secondary end points included safety and predictive impact of early response on pCR. Adjuvant therapy followed national standards. Results Baseline characteristics were well balanced among the arms. More than 90% of patients completed the therapy per protocol. pCR was observed in 41.0% of patients treated with T-DM1, 41.5% of patients treated with T-DM1 and ET, and 15.1% with trastuzumab and ET ( P < .001). Early responders (67% of patients with assessable response) achieved pCR in 35.7% compared with 19.8% in nonresponders (odds ratio, 2.2; 95% CI, 1.24 to 4.19). T-DM1 was associated with a significantly higher prevalence of grade 1 to 2 toxicities, especially thrombocytopenia, nausea, and elevation of liver enzymes. Overall toxicity was low; seventeen therapy-related severe adverse events (T-DM1 arms v trastuzumab plus ET; 5.3% v 3.1%, respectively) were reported. Conclusion The ADAPT HER2-positive/HR-positive trial demonstrates that neoadjuvant T-DM1 (with or without ET) given for only 12 weeks results in a clinically meaningful pCR rate. Thus, a substantial number of patients are spared the adverse effects of systemic chemotherapy.
引用
- Harbeck N, Gluz O, Christgen M, et al. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J Clin Oncol. 2017. PMID: 28682681. doi:10.1200/JCO.2016.71.9815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。